Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
Currently, there has been a marked increase in the number of opportunities for relapsed and refractory multiple myeloma treatment due to emergence of new target drugs. These include pomalidomide, a 3 rd generation immunomodulator capable of treating double refractory multiple myeloma (to lenalidomid...
Saved in:
| Main Authors: | I. G. Rekhtina, L. P. Mendeleeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
by: AV Petrov, et al.
Published: (2017-07-01) -
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01) -
The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
by: IG Rekhtina, et al.
Published: (2018-10-01) -
PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01) -
Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)